Sciwind Biosciences Co., Ltd. is established in 2017, with headquarter in Hangzhou city and R&D center located in Beijing. We focus on developing and commercializing innovative, best-in-class protein/peptide drugs for treating diseases in multiple therapeutic areas, including diabetes, obesity, metabolic diseases, diabetic retinopathy/macular edema and neuro-degenerative diseases (AD and PD).
Our highly international teams received PhD/Master’s degrees from US, Canada and China, with global R&D and management experience in Amgen, Wyeth/Pfizer and Novo Nordisk.
Our core team members have demonstrated expertise and experience in all areas of drug development, from discovery, early preclinical till late clinical development in global pharmaceutical companies.
We are committed to deliver best-in-class, innovative, safe and efficacious biological medicines to patients in the world.